Excited to keynote Jefferson Advances in Liver Diseases 2024 conference on Sat! I'll be sharing insights from AASLD
#TLM24 on #MASLD biomarkers, unmet clinical needs, emerging Rx and more!
(PS-great weekend to be in Philly- Eagles v Steelers!)
jefferson.cloud-cme.com/course/cours...
More virtual participants than in person. How do you mute all in zoom?
#HBV #TLM24 debrief
Colina Yim back as translator
It was great catching up with @dougsimonetto.bsky.social at #TLM24 Doug is the program director for GI fellowship at @mayoclinic.bsky.social Rochester.
Blue sky from Australia 🇦🇺
Nice to be back at home 🏡 although I miss San Diego and all the excitement of #TLM24
After a successful #TLM24 AASLD in San Diego - thanks Ray Kim and Paul Kwo for a fantastic hospitality at @stanfordpress.bsky.social
Hello Ahmed 👋
Welcome 🤗
You can find some of my #TLM24 coverage about viral hepatitis using #Liversky
( #HepSky didn’t exist at the time lol)
HBsAg loss & seroconversion in HBeAg- chronic hep B subjects on NA Tx after AHB-137 Tx: preliminary data, multicenter, rando, open-label phase 2a #TLM24
w24 (EOT, on going)
• HBsAg ⬇️ 78% >3log10
• HBsAg loss 69%(!)
*My take: AHB-137= better Bepirovirsen (ASO)?
To be continued 😮
#Liversky #IDsky
Safety & efficacy of REP 2139-Mg in hepatitis D patients: reporting of extended follow-up data from the international compassionate use program #TLM24
⚠️ I have a strong optimism bias because my 🇨🇦 patient (the only 🇨🇦 patient in the program,PLWH compensated cirrhosis) is HDV RNA TND at ~24w off Tx❗)
Tobevibart (VIR-3434; mAb inhibition of viral entry ) and elebsiran (VIR-2218; siRNA HBV mRNAs) +/- pegIFNa-2a for the treatment of chronic HBV infection:
End of treatment results after 48 weeks of therapy (MARCH study)
#TLM24
(1/2)
One of my absolute favorite parts of this weekend at #TLM24 was picking up some educational materials @KnowledgeNash table.
Livvy the liver !!! How cute is this coloring to raise awareness on fatty liver disease for kids !
That’s great. Sorry I didn’t see you or PPB at the #TLM24
Leaving the sunny blue sky of San Diego after a fabulous #TLM24
Watch this space for the Australian summer blue sky photos once I get back home after a 24 hr travel!
Every time I come here, I feel at home. This has always been a great country. Stay safe everyone! Good bye for now 😍
HBs isoforms as innovative biomarkers in predicting virological response to bulevirtide monotherapy in patients with chronic hepatitis delta #TLM24
➡️ Quantification of L-HBs & serum HDV-RNA may be a new tool to identify patients more likely to respond to bulevirtide monotherapy 🤔
#Liversky #IDsky
Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: Week 24 primary endpoint analysis from the Phase 2 SOLSTICE trial #TLM24
❗Exciting times ahead for Hepatitis Delta 😮
I can’t believe #TLM24 is over. Honored and looking forward to the next 2 yr as Chair of the Hep Assoc SIG and invited guest of the Governing Board representing #HepatologyAssociates.
❗Very impressive data 👀
by Bluejay therapeutics #TLM24
BJT-778,anti-HBsAg monoclonal Ab, achieved 100% virologic response in subjects w/ chronic hep D : phase 2
BJT-778 MoA
-Neutralize infectious HBV & HDV
-Deplete HBsAg-contained particles
-Presentation to & activation of T cell
#Liversky #IDSky
A great meeting #TLM24 comes to an end. As I sit quietly in a restaurant all by myself for a quiet meal tonight, (flying out in the morning) I come across this on Facebook. Perfectly captures the mood on blue sky.
Heading home from AASLD #TLM24 at 30,000 ft 🛫 and learned:
1) our manuscript resulting from a collaboration with Drs. Ravi Patel at UPMC and Rosa Nguyen at NCI just got accepted
2) grant with Rosa just got funded.
Time to get a lottery ticket?
#radiopharmaceuticals
A Prospective / Retrospective Provincial and National Laboratory Serosurvey of HDV Antibody Prevalence in Referred & Non-Referred Samples in 🇨🇦 #TLM24
+52 patients were identified with anti-HDV in the non-referred population that would have otherwise been missed using the High Risk approach
(1/3)
Question for #LivSky #TLM24: Looking at abstract 5025 testing imdusiran & VTP-300 with or without nivolumab for non-cirrhotic hepatitis B. Given that well-tolerated generic antivirals can keep HBV suppressed indefinitely, why would you subject pts to cost & adverse events of a checkpoint inhibitor?
2/3
There has been sessions such as MTE and mock tumor boards that have achieved this.
However, I applaud @AASLDtweets & @AASLDPresident for accepting our “community conversation” proposal to discuss “how to apply guidelines and scientific evidence to every day care”.
#TLM24
1/3 What happens when science and every day clinical practice comes together?
A 🧵
You get a packed room with not even a place to stand 👇🏼
Why?
I firmly believe that we need to bridge the gap between research and clinical application in our scientific meetings.
#TLM24
Yes! Despite my bias towards SoMe and teams meeting, I agree that nothing replaces in-person meeting! #TLM24
Great to see you and @drjessicadavis.bsky.social here!!!
That said, it was waaay better to see you in person at #TLM24
Ceviche, aguachile, and campechano in San Diego
Dear San Diego,
So long and thanks for all the fish!
Regards,
#tlm24
